Wells Fargo’s 10x Genomics TXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-1,800
Closed -$137K 7511
2022
Q1
$137K Buy
+1,800
New +$157K ﹤0.01% 5176

Other funds holding TXG

Wells Fargo's TXG Position: Q1 2026 in Review

Wells Fargo reduced its 10x Genomics (TXG) stake by 59% in Q1 2026, selling an estimated $4.09M and leaving 140,116 shares worth $2.97M. The position accounts for ﹤0.01% of the portfolio, ranked #2979.

Wells Fargo first reported a position in TXG in Q3 2019 and has held it in 27 quarters since. The position peaked at $150M in Q2 2021. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

  • Wells Fargo held 140,116 shares of 10x Genomics worth $2.97M as of Q1 2026.
  • Wells Fargo sold 204,834 10x Genomics shares in Q1 2026, an estimated $4.09M.
  • 10x Genomics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #2979 holding.
  • Wells Fargo first reported a position in 10x Genomics in Q3 2019 and has held it in 27 quarters since.
  • Wells Fargo's 10x Genomics position peaked at $150M in Q2 2021.
  • 329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.